Mizuho Upgrades Guardant Health (NASDAQ:GH) to Strong-Buy

Guardant Health (NASDAQ:GH) was upgraded by Mizuho to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Other research analysts have also recently issued reports about the company. Raymond James reiterated an “outperform” rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Barclays cut their target price on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday. Piper Sandler increased their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Stifel Nicolaus lifted their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Stephens reiterated an “overweight” rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $49.00.

Guardant Health Trading Up 1.4 %

Shares of GH stock traded up $0.59 during trading hours on Wednesday, hitting $41.73. The company’s stock had a trading volume of 123,834 shares, compared to its average volume of 2,127,475. The stock has a market cap of $5.15 billion, a PE ratio of -11.67 and a beta of 1.45. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89. The company has a 50 day moving average of $43.64 and a 200 day moving average of $35.54.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, analysts anticipate that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Institutional Trading of Guardant Health

Several large investors have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in Guardant Health by 16.2% during the third quarter. Janus Henderson Group PLC now owns 60,578 shares of the company’s stock worth $1,390,000 after buying an additional 8,432 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after acquiring an additional 29,686 shares during the period. Exome Asset Management LLC boosted its position in shares of Guardant Health by 13.7% during the 3rd quarter. Exome Asset Management LLC now owns 89,800 shares of the company’s stock valued at $2,060,000 after acquiring an additional 10,800 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Guardant Health in the third quarter valued at about $15,624,000. Finally, Fiduciary Alliance LLC increased its position in Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock worth $363,000 after purchasing an additional 836 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.